{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:50:40Z","timestamp":1790567440294,"version":"4.1.0"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Res"],"abstract":"<jats:p>Introduction: Systemic implications create a critical need for identification of dry eye patients with Sj\u00f6gren syndrome (SS). Herein, we aim to determine expressions of type I-III interferons (IFNs) in dry eye patients with or without underlying SS and their differential diagnosis.\nMethods: A prospective, observational, case-control study was performed on 140 dry eye patients among which 78 patients were diagnosed with SS. Clinical evaluations included ELISA detections of serum type I IFN (IFN-\u03b1 and IFN-\u03b2, type II IFN (IFN-\u03b3), and type III IFN (IFN-\u03bb1\/IL-29, IFN-\u03bb2\/IL-28, and IFN-\u03bb3\/IL-28B), as well as reporter cell assay for serum type I IFN activity.\nResults: The serum levels of IFN-\u03b1 and IFN-\u03b2 were notably higher in dry eye patients with SS than those without underlying SS (p &amp;lt; 0.0001). The functional assay for serum type I IFN activity showed the mean summed scores in dry eye patients with SS were remarkably increased compared to those without underlying SS (p &amp;lt; 0.0001). The serum levels of IFN-\u03b3 and IFN-\u03bb1\/IL-29 seemed higher in dry eye patients with SS than those without underlying SS (p &amp;lt; 0.0001). The serum levels of type I IFN (IFN-\u03b1 combined with IFN-\u03b2), type II IFN (IFN-\u03b3 level), and type III IFN (IFN-\u03bb1\/IL-29) used as a test to predict underlying SS among dry eye patients produced an AUC of 0.86, 0.73, and 0.94, respectively.\nConclusion: Serum levels of type I-III IFNs, especially IFN-\u03b1, IFN-\u03b2, and IFN-\u03bb1\/IL-29, may serve as a useful biomarker for identification of SS dry eye from non-SS dry eye.<\/jats:p>","DOI":"10.1159\/000540295","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T21:01:22Z","timestamp":1722632482000},"source":"Crossref","is-referenced-by-count":1,"title":["Expressions of type I-III interferons in Sj\u00f6gren's syndrome and non-Sj\u00f6gren's dry eye"],"prefix":"10.1159","author":[{"given":"Nan","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanpeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjuan","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixiong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2024,8,2]]},"container-title":["Ophthalmic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/ore\/article-pdf\/doi\/10.1159\/000540295\/4260852\/000540295.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/ore\/article-pdf\/doi\/10.1159\/000540295\/4260852\/000540295.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:30:32Z","timestamp":1745422232000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000540295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,2]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000540295","archive":["Portico"],"relation":{},"ISSN":["0030-3747","1423-0259"],"issn-type":[{"value":"0030-3747","type":"print"},{"value":"1423-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,2]]}}}